These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 37722358)

  • 1. Synergistic Approach of Antibody-Photosensitizer Conjugate Independent of KRAS-Mutation and Its Downstream Blockade Pathway in Colorectal Cancer.
    Ahn M; Lee T; Kim KS; Lee S; Na K
    Adv Healthc Mater; 2023 Dec; 12(31):e2302374. PubMed ID: 37722358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune Stimulating Antibody-Photosensitizer Conjugates via Fc-Mediated Dendritic Cell Phagocytosis and Phototriggered Immunogenic Cell Death for KRAS-Mutated Pancreatic Cancer Treatment.
    Kim D; Lee S; Na K
    Small; 2021 Mar; 17(10):e2006650. PubMed ID: 33590726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cetuximab Enhances the Efficacy of MRTX1133, a Novel KRAS
    Kataoka M; Kitazawa M; Nakamura S; Koyama M; Yamamoto Y; Miyazaki S; Hondo N; Tanaka H; Soejima Y
    Anticancer Res; 2023 Oct; 43(10):4341-4348. PubMed ID: 37772552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab.
    Lee SK; Cho YH; Cha PH; Yoon JS; Ro EJ; Jeong WJ; Park J; Kim H; Il Kim T; Min DS; Han G; Choi KY
    Exp Mol Med; 2018 Nov; 50(11):1-12. PubMed ID: 30459318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Promising Therapeutic Efficacy of GC1118, an Anti-EGFR Antibody, against KRAS Mutation-Driven Colorectal Cancer Patient-Derived Xenografts.
    Lee HW; Son E; Lee K; Lee Y; Kim Y; Lee JC; Lim Y; Hur M; Kim D; Nam DH
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31771279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Andrographolide sensitizes KRAS-mutant colorectal cancer cells to cetuximab by inhibiting the EGFR/AKT and PDGFRβ/AKT signaling pathways.
    Liu YF; Feng ZQ; Chu TH; Yi B; Liu J; Yu H; Xue J; Wang YJ; Zhang CZ
    Phytomedicine; 2024 Apr; 126():155462. PubMed ID: 38394734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
    Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
    Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
    Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
    Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
    Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MEK inhibitor and anti-EGFR antibody overcome sotorasib resistance signals and enhance its antitumor effect in colorectal cancer cells.
    Hondo N; Kitazawa M; Koyama M; Nakamura S; Tokumaru S; Miyazaki S; Kataoka M; Seharada K; Soejima Y
    Cancer Lett; 2023 Jul; 567():216264. PubMed ID: 37336286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD16-158-valine chimeric receptor T cells overcome the resistance of KRAS-mutated colorectal carcinoma cells to cetuximab.
    Arriga R; Caratelli S; Lanzilli G; Ottaviani A; Cenciarelli C; Sconocchia T; Spagnoli GC; Iezzi G; Roselli M; Lauro D; Coppola A; Dotti G; Ferrone S; Sconocchia G
    Int J Cancer; 2020 May; 146(9):2531-2538. PubMed ID: 31396956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-Metastatic Activity of an Anti-EGFR Monoclonal Antibody against Metastatic Colorectal Cancer with
    Ohishi T; Kato Y; Kaneko MK; Ohba SI; Inoue H; Harakawa A; Kawada M
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32839411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting cetuximab accumulation in KRAS wild-type and KRAS mutant colorectal cancer using 64Cu-labeled cetuximab positron emission tomography.
    Achmad A; Hanaoka H; Yoshioka H; Yamamoto S; Tominaga H; Araki T; Ohshima Y; Oriuchi N; Endo K
    Cancer Sci; 2012 Mar; 103(3):600-5. PubMed ID: 22126621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-MEK and Anti-EGFR mAbs in RAS-Mutant Metastatic Colorectal Cancer: Case Series and Rationale.
    Ledys F; Derangère V; Réda M; Guion JF; Milliex R; Roux V; Limagne E; Arnould L; Bengrine L; Ghiringhelli F; Rébé C
    Adv Ther; 2019 Jun; 36(6):1480-1484. PubMed ID: 30980281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGFR Blockade Reverts Resistance to KRAS
    Amodio V; Yaeger R; Arcella P; Cancelliere C; Lamba S; Lorenzato A; Arena S; Montone M; Mussolin B; Bian Y; Whaley A; Pinnelli M; Murciano-Goroff YR; Vakiani E; Valeri N; Liao WL; Bhalkikar A; Thyparambil S; Zhao HY; de Stanchina E; Marsoni S; Siena S; Bertotti A; Trusolino L; Li BT; Rosen N; Di Nicolantonio F; Bardelli A; Misale S
    Cancer Discov; 2020 Aug; 10(8):1129-1139. PubMed ID: 32430388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phellinus linteus Grown on Germinated Brown Rice Increases Cetuximab Sensitivity of KRAS-Mutated Colon Cancer.
    Park HJ; Park JB; Lee SJ; Song M
    Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28800074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methylglyoxal Scavengers Resensitize KRAS-Mutated Colorectal Tumors to Cetuximab.
    Bellier J; Nokin MJ; Caprasse M; Tiamiou A; Blomme A; Scheijen JL; Koopmansch B; MacKay GM; Chiavarina B; Costanza B; Rademaker G; Durieux F; Agirman F; Maloujahmoum N; Cusumano PG; Lovinfosse P; Leung HY; Lambert F; Bours V; Schalkwijk CG; Hustinx R; Peulen O; Castronovo V; Bellahcène A
    Cell Rep; 2020 Feb; 30(5):1400-1416.e6. PubMed ID: 32023458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting RAS signaling pathway as a potential therapeutic target in the treatment of colorectal cancer.
    Bahrami A; Hassanian SM; ShahidSales S; Farjami Z; Hasanzadeh M; Anvari K; Aledavood A; Maftouh M; Ferns GA; Khazaei M; Avan A
    J Cell Physiol; 2018 Mar; 233(3):2058-2066. PubMed ID: 28262927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cetuximab inhibits gastric cancer growth in vivo, independent of KRAS status.
    Shi M; Shi H; Ji J; Cai Q; Chen X; Yu Y; Liu B; Zhu Z; Zhang J
    Curr Cancer Drug Targets; 2014; 14(2):217-24. PubMed ID: 24467518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
    Lee J; Lee I; Han B; Park JO; Jang J; Park C; Kang WK
    J Natl Cancer Inst; 2011 Apr; 103(8):674-88. PubMed ID: 21398618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.